{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:14:28Z","timestamp":1763003668238,"version":"3.45.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jtct.2023.11.004","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T07:40:54Z","timestamp":1701157254000},"page":"727-729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Autologous Stem Cell Transplant in Ultra-High-Risk Myeloma: Do the Ends Still Justify the Means?"],"prefix":"10.1016","volume":"29","author":[{"given":"Barry","family":"Paul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.11.004_bib0001","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/095952874402700129","article-title":"Remarks on the pathology of mollities ossium; with cases","volume":"27","author":"Solly","year":"1844","journal-title":"Medico-chirurgical transactions"},{"key":"10.1016\/j.jtct.2023.11.004_bib0002","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.11.004_bib0003","first-page":"2955","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/j.jtct.2023.11.004_bib0004","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"American journal of hematology"},{"key":"10.1016\/j.jtct.2023.11.004_bib0005","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-020-00347-6","article-title":"Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis","volume":"10","author":"Derman","year":"2020","journal-title":"Blood cancer journal"},{"key":"10.1016\/j.jtct.2023.11.004_bib0006","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/j.jtct.2023.11.004_bib0007","first-page":"1308","article-title":"Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del (1p32) remains a strong prognostic factor","volume":"141","author":"Schavgoulidze","year":"2023","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/j.jtct.2023.11.004_bib0008","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jtct.2023.11.004_bib0009","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.11.004_bib0010","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.jtct.2023.11.004_bib0011","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.jtct.2023.11.004_bib0012","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","author":"Richardson","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jtct.2023.11.004_bib0013","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jtct.2023.11.004_bib0014","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.bbmt.2016.07.007","article-title":"Post-transplant outcomes in high-risk compared with non\u2013high-risk multiple myeloma: a CIBMTR analysis","volume":"22","author":"Scott","year":"2016","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.jtct.2023.11.004_bib0015","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jtct.2023.08.031","article-title":"Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma","volume":"29","author":"Pasvolsky","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.11.004_bib0016","first-page":"2020","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"1928","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jtct.2023.11.004_bib0017","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.jtct.2023.11.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","author":"Costa","year":"2023","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.jtct.2023.11.004_bib0019","doi-asserted-by":"crossref","first-page":"10144","DOI":"10.1182\/blood-2022-160451","article-title":"Analysis of transplant-eligible patients (Pts) who received frontline daratumumab (DARA)-Based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM) with high-risk cytogenetic abnormalities (HRCA) in the Griffin and Master studies","volume":"140","author":"Callander","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.11.004_bib0020","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer cell"},{"key":"10.1016\/j.jtct.2023.11.004_bib0021","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","author":"San-Miguel","year":"2023","journal-title":"New England Journal of Medicine"},{"year":"2023","series-title":"First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma","author":"Dhakal","key":"10.1016\/j.jtct.2023.11.004_bib0022"},{"key":"10.1016\/j.jtct.2023.11.004_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Frontiers in immunology"},{"key":"10.1016\/j.jtct.2023.11.004_bib0024","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2021-146210","volume":"138","author":"Dytfeld","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.11.004_bib0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2022-162395","volume":"140","author":"Bal","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.11.004_bib0026","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jtct.2023.11.004_bib0027","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jtct.2023.11.004_bib0028","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"European journal of clinical investigation"},{"key":"10.1016\/j.jtct.2023.11.004_bib0029","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood advances"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723016512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723016512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:11:23Z","timestamp":1763003483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723016512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2666636723016512"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.11.004","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Autologous Stem Cell Transplant in Ultra-High-Risk Myeloma: Do the Ends Still Justify the Means?","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}